AR077664A2 - Compuestos como ligandos de receptores de canabinoides - Google Patents

Compuestos como ligandos de receptores de canabinoides

Info

Publication number
AR077664A2
AR077664A2 ARP100102555A ARP100102555A AR077664A2 AR 077664 A2 AR077664 A2 AR 077664A2 AR P100102555 A ARP100102555 A AR P100102555A AR P100102555 A ARP100102555 A AR P100102555A AR 077664 A2 AR077664 A2 AR 077664A2
Authority
AR
Argentina
Prior art keywords
cr1cr1d
haloalkyl
alkyl
independently
instance
Prior art date
Application number
ARP100102555A
Other languages
English (en)
Inventor
William A Carrol
Michael J Dart
Jennifer M Frost
Steven P Latshaw
Teodozyj Kolasa
Tongmei Li
Sridhar Peddi
Bo Liu
Arturo Perez-Medrano
Meena V Patel
Xeuqing Wang
Derek W Nelson
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41210849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077664(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR077664A2 publication Critical patent/AR077664A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Se divulgan asimismo composiciones que comprenden dichos compuestos y métodos para el tratamiento de condiciones y trastornos usando dichos compuestos y composiciones para diabetes, trastornos cardiovasculares y del sistema nervioso central. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), o una sal, solvato, prodroga, o sal de prodroga farmacéuticamente aceptable o combinacion de los mismos donde X4 es O, S, S(O), S(O)2, o N(Rbx); donde Rbx es hidrogeno, alquilo, haloalquilo, alcoxialquilo, -C(O)O(alquilo), cicloalquilo monocíclico, -(CR1cR1d)q3-(cicloalquilo monocíclico), o haloalcoxialquilo; y A1 es -G1a-G1b, -(CR1aR1b)q1-G1c, -(CR1aR1b)q1-A2, -(CR1gR1h)q2-A4, -N(Rb)C(O)Ra, -N(Rb)C(O)ORd, -N(Rb)C(O)N(Rb)(Rc), -N(Rb)(Rc), o -N=C(Rp)Rq); o X4 y A1 juntos son N=N(Rcx); A2 es -C(O)Ra, -S(O)2Rd, -SRd, -C(O)ORa, -C(O)N(Rb)(Rc), -C(S)N(Rb)(Rc), -S(O)2N(Rb)(Rc), -C(=NORf)Ra, -CN, -N(Rc)C(O)Ra, -N(Rc)C(O)ORd, -N(Rc)S(O)2Rd, -N(Rc)C(O)N(Rb)(Rc), -N(Rc)S(O)2N(Rb)(Rc), -ORm, o -N(Rb)(Rn); A3 es C(O)Rh, -S(O)2Re, -C(O)N(Rh)2, -C(S)N(Rh)2, -S(O)2N(Rh)2, -C(=NORh)Rh, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, -N(Rh)S(O)2Re, -N(Rh)C(O)N(Rh)2, -N(Rh)S(O)2N(Rh1)2, -CN, -ORh, o -N(Rh)2; A4 es cicloalquilo, alcoxi, haloalcoxi, o N(R1m)2 donde cada instancia de R1m es en forma independiente hidrogeno o alquilo; cada instancia de Ra y Rc, es en forma independiente hidrogeno, alquilo, haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rb, en cada instancia, es en forma independiente hidrogeno, alquilo, haloalquilo, alcoxialquilo, cicloalquilo monocíclico, -(CR1cR1d)q3-(cicloalquilo monocíclico), o haloalcoxialquilo; Rd, en cada instancia, es en forma independiente alquilo, haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rcx es alquilo, haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rm es hidrogeno, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rn es haloalquilo, -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; Rp es hidrogeno, alquilo, haloalquilo, -(CR1aR1b)q3-A3, -C(O)ORd, -C(O)Rd, G1d, o -(CR1aR1b)q3-G1d; Rq es hidrogeno, alquilo, haloalquilo, -N(Rb)(Rc), -(CR1aR1b)q3-A3, G1d, o -(CR1aR1b)q3-G1d; o Rp y Rq, junto con el átomo de carbono al cual están unidos, forman un anillo monocíclico de 5, 6, 7 u 8 miembros, opcionalmente sustituido con 1, 2, 3, 4, o 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en oxo, alquilo, haloalquilo, y halogeno; A5 representa la formula (a), (b), (c), (d), o (e), G1a y G1b son en forma independiente cicloalquilo, cicloalquenilo, heterociclo, arilo, o heteroarilo; G1c es cicloalquenilo, heterociclo, arilo, o heteroarilo; el anillo representado por G1a está opcionalmente sustituido con 1, 2, 3, 4, o 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, alquenilo, alquinilo, halogeno, haloalquilo, =N-CN, =N-ORf, -CN, oxo, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, -N(Rf)S(O)2Re, -N(Rf)C(O)O(Re), -N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2, y -(CR1cR1d)q3-CN; los anillos representados por G1b, G1c, y el cicloalquilo de A4 están opcionalmente sustituidos en cada caso con 1, 2, 3, 4, o 5 sustituyentes seleccionados en forma independiente entre el grupo que consiste G1d, alquilo, alquenilo, alquinilo, halogeno, haloalquilo, =N-CN, =N-ORf, -CN, oxo, -ORf, -OC(O)Rf -OC(O)N(Rf)2, -S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, -N(Rf)S(O)2Re, -N(Rf)C(O)O(Re), -N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-G1d, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2 y -(CR1cR1d)q3-CN; G1d, en cada instancia, es en forma independiente un heterociclo monocíclico, un heteroarilo monocíclico, un fenilo, un cicloalquilo monocíclico, o un cicloalquenilo monocíclico; donde G1d está opcionalmente sustituido con 1, 2, 3, o 4 sustituyentes seleccionados en forma independiente entre el grupo que consiste en -N(Rh)2, -CN, oxo, alquilo, haloalquilo, alcoxi, haloalcoxi, halogeno, y OH; Re, en cada instancia, es en forma independiente alquilo C1-4, haloalquilo C1-4, cicloalquilo monocíclico, heterociclo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); Rf, en cada instancia, es en forma independiente hidrogeno, alquilo C1-4, haloalquilo C1-4, -(CR1cR1d)q3-ORh, heterociclo monocíclico, cicloalquilo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); Rh, en cada instancia, es en forma independiente hidrogeno, alquilo C1-4, haloalquilo C1-4, cicloalquilo monocíclico, o -(CR1cR1d)q3-(cicloalquilo monocíclico); R21, R22, R23, R24, y R25 es en forma independiente alquilo, alquenilo, alquinilo, haloalquilo, -(CR2aR2b)q4-OH, -(CR2aR2b)q4-O-aIquilo, -(CR2aR2b)q4-O-haloalquilo, -(CR2aR2b)q4-O-G2a, -(CR2aR2b)q4-O-(CR2cR2d)q3-G2a, -(CR2aR2b)q5-C(O)-Ra, -(CR2aR2b)q5-C(=N-ORf)Ra, -(CR2aR2b)q5-SO2-Rd, -(CR2aR2b)q5-G2b, -(CR2aR2b)q5-C(O)N(Rb)(Rc), o -(CR2aR2b)q5-CN; cada instancia de G2a es en forma independiente cicloalquilo, heterociclo, arilo, o heteroarilo; G2b es un anillo monocíclico seleccionado entre el grupo que consiste en cicloalquilo, cicloalquenilo, tienilo, fenilo, furanilo, oxazolilo, isoxazolilo, oxadiazolilo, y heterociclo; donde el heterociclo contiene 0 o 1 doble enlace, 1 o 2 oxígenos, y 0 o 1 nitrogeno como átomos del anillo; dos átomos no adyacentes de dicho anillo heterociclo pueden estar opcionalmente unidos por medio de un puente alquenileno de 2, 3, o 4 átomos de carbono, u opcionalmente unidos por un puente alquileno de 1, 2, 3, o 4 átomos de carbono; cada anillo G2b está opcionalmente fusionado con un anillo monocíclico seleccionado entre el grupo que consiste en benzo, cicloalquilo, cicloalquenilo, heterociclo y heteroarilo; cada instancia de G2a y G2b en forma independiente no está sustituida o está sustituida con 1, 2, 3, 4, 5, o 6 sustituyentes seleccionados en forma independiente entre el grupo que consiste en oxo, alquilo, halogeno, -OH, alcoxi, haloalcoxi, y haloalquilo; X1 es O o S; X2 es O, S, o N(R10) donde R10 es alquilo, alcoxialquilo, haloalcoxialquilo, o haloalquilo; X3 es O o S; R3, R4, R5, R6, R7, R8, R9, R11, y R12 es en forma independiente G3, hidrogeno, alquilo, alquenilo, alquinilo, -NO2, -CN, halogeno, -ORh, N(Rh)2, - C(O)Rh, -C(O)O(Rh), haloalquilo, -(CR3aR3b)q6-ORh, -(CR3aR3b)q6-N(Rh)2, -(CR3aR3b)q6-C(O)Rh, o -(CR3aR3b)q6-C(O)O(Rh); R13 y R14 es en forma independiente G3, hidrogeno, alquilo, haloalquilo, o -(CR3aR3b)q6-ORh; o R13 y R14 tomados junto con el átomo de carbono al cual están unidos forman un anillo heterociclo monocíclico o un anillo cicloalquilo monocíclico, donde cada uno de los cuales en forma independiente no está sustituido o está sustituido con 1, 2, 3, o 4 sustituyentes seleccionados entre el grupo que consiste en alquilo, OH, alcoxi, haloalcoxi, haloalquilo, y oxo; R15 y R16 es en forma independiente G3, hidrogeno, alquilo, haloalquilo, o -(CR3aR3b)q6-ORh; o R5 y R16 tomados junto con el átomo de carbono al cual están unidos forman un anillo cicloalquilo monocíclico o un anillo heterociclo monocíclico; donde cada uno de los cuales en forma independiente no está sustituido o está sustituido con 1, 2, 3, o 4 sustituyentes seleccionados entre el grupo que consiste en alquilo, OH, alcoxi, haloalcoxi, haloalquilo, y oxo; G3, en cada instancia, es en forma independiente cicloalquilo, cicloalquenilo, arilo, heterociclo, o heteroarilo, donde cada G3 en forma independiente no está sustituida o está sustituida con 1, 2, 3 o 4 sustituyentes seleccionados entre el grupo que consiste en alquilo C1-4, alquenilo C2-4, alquinilo C2-4, halogeno, haloalquilo C1-4, =N-CN, =N-ORh, -CN, oxo, -ORh, -OC(O)Rh, -OC(O)N(Rh)2, -S(O)2Re, -S(O)2N(Rh)2, -C(O)Rh, -C(O)Orh, -C(O)N(Rh)2, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)S(O)2Re, -N(Rh)C(O)O(Re), y -N(Rh)C(O)N(Rh)2; R1a en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4 o haloalquilo C1-4; R1b en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, alquenilo C2-4, haloalquilo C1-4, -ORh, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, o -N(Rh)S(O)2Re; R1g en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, haloalquilo C1-4, -ORh, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, o -N(Rh)S(O)2Re; con la condicion de que al menos una instancia de R1g es halogeno, haloalquilo C1-4, -ORh, -N(Rh)2, -N(Rh)C(O)Rh, -N(Rh)C(O)ORe, o -N(Rh)S(O)2Re; R1h, en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, o haloalquilo C1-4; R1c, R1d, R2a, R2b, R2c, R2d, R3a y R3b, en cada instancia, es en forma independiente hidrogeno, halogeno, alquilo C1-4, o haloalquilo C1-4; Rx en cada instancia, es en forma independiente G1d, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, halogeno, haloalquilo C1-4, NO2, -CN, -ORf, -OC(O)Rf, -OC(O)N(Rf)2, S(O)2Re, -S(O)2N(Rf)2, -C(O)Rf, -C(O)ORf, -C(O)N(Rf)2, -N(Rf)2, -N(Rf)C(O)Rf, -N(Rf)S(O)2Re, -N(Rf)C(O)O(Re), -N(Rf)C(O)N(Rf)2, -(CR1cR1d)q3-ORf, -(CR1cR1d)q3-OC(O)Rf, -(CR1cR1d)q3-OC(O)N(Rf)2, -(CR1cR1d)q3-S(O)2Re, -(CR1cR1d)q3-S(O)2N(Rf)2, -(CR1cR1d)q3-C(O)Rf, -(CR1cR1d)q3-C(O)ORf, -(CR1cR1d)q3-C(O)N(Rf)2, -(CR1cR1d)q3-N(Rf)2, -(CR1cR1d)q3-N(Rf)C(O)Rf, -(CR1cR1d)q3-N(Rf)S(O)2Re, -(CR1cR1d)q3-N(Rf)C(O)O(Re), -(CR1cR1d)q3-N(Rf)C(O)N(Rf)2, o -(CR1cR1d)q3-CN; q1, en cada instancia, es en forma independiente 1, 2, 3, o 4; q2 y q4, en cada instancia, son en forma independiente 2, 3, 4, o 5; q3, en cada instancia, es 1, 2 o 3; q5 y q6, en cada instanc
ARP100102555A 2008-09-16 2010-07-14 Compuestos como ligandos de receptores de canabinoides AR077664A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9737808P 2008-09-16 2008-09-16
US22420009P 2009-07-09 2009-07-09

Publications (1)

Publication Number Publication Date
AR077664A2 true AR077664A2 (es) 2011-09-14

Family

ID=41210849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103558A AR073599A1 (es) 2008-09-16 2009-09-16 Compuestos heterociclicos como ligandos de receptores de canabinoides
ARP100102555A AR077664A2 (es) 2008-09-16 2010-07-14 Compuestos como ligandos de receptores de canabinoides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090103558A AR073599A1 (es) 2008-09-16 2009-09-16 Compuestos heterociclicos como ligandos de receptores de canabinoides

Country Status (23)

Country Link
US (2) US8188135B2 (es)
EP (3) EP2428507B1 (es)
JP (1) JP2012502917A (es)
KR (1) KR20110061619A (es)
CN (1) CN102216277A (es)
AR (2) AR073599A1 (es)
AU (1) AU2009293319A1 (es)
BR (1) BRPI0919135A2 (es)
CA (1) CA2737199A1 (es)
CL (1) CL2011000544A1 (es)
CO (1) CO6361998A2 (es)
DO (1) DOP2011000081A (es)
EC (1) ECSP11010974A (es)
ES (1) ES2556752T3 (es)
IL (1) IL211406A0 (es)
MX (1) MX2011002811A (es)
PA (1) PA8842501A1 (es)
PE (1) PE20110804A1 (es)
RU (1) RU2011115087A (es)
TW (1) TW201016692A (es)
UY (1) UY32125A (es)
WO (1) WO2010033543A2 (es)
ZA (1) ZA201101590B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140439A2 (en) * 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
US8841334B2 (en) * 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
RU2008152788A (ru) * 2006-05-31 2010-07-10 Эбботт Лэборетриз (Us) Новые соединения в качестве лигандов каннабиноидных рецепторов и их применение
MX2009010363A (es) 2007-03-28 2009-12-04 Abbott Lab Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide.
US7872033B2 (en) * 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
CA2683086A1 (en) * 2007-05-18 2008-11-18 Abbott Laboratories Color tunable light source
US9193713B2 (en) * 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2009114566A1 (en) 2008-03-11 2009-09-17 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010033543A2 (en) * 2008-09-16 2010-03-25 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
EP2411371B1 (en) 2009-03-27 2015-05-20 AbbVie Inc. Compounds as cannabinoid receptor ligands
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands
CN103396376B (zh) * 2013-07-31 2016-08-10 杨文茂 一种抗菌抗癌活性化合物
JP6616785B2 (ja) * 2014-05-19 2019-12-04 シンジェンタ パーティシペーションズ アーゲー 硫黄置換フェニル基またはピリジン基を有する殺虫的に活性なアミド誘導体
KR20170072876A (ko) * 2014-10-27 2017-06-27 에프. 호프만-라 로슈 아게 방사성 표지된 카나비노이드 수용체 2 리간드
CN106749078B (zh) * 2015-11-23 2019-01-04 中国科学院大连化学物理研究所 一种2-亚胺基恶唑的合成方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1522361A1 (de) 1966-03-08 1969-07-24 Agfa Gevaert Ag Sensibilisierung lichtempfindlicher Polymerer
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
DE1772867A1 (de) 1968-07-15 1971-06-16 Agfa Gevaert Ag Sensibilisierung von Schichten aus lichtvernetzbaren Polymeren
JPS5089367A (es) 1973-12-14 1975-07-17
JPS57171986A (en) 1981-04-14 1982-10-22 Taiho Yakuhin Kogyo Kk Heterocylic ring compound containing sulfur
DE3333450A1 (de) 1983-09-16 1985-04-11 Hoechst Ag, 6230 Frankfurt Trihalogenmethylgruppen enthaltende carbonylmethylenheterocyclen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindungen enthaelt
US4978664A (en) 1984-08-06 1990-12-18 Sterling Drug Inc. 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indole pharmaceutical compositions
US4885295A (en) 1984-08-06 1989-12-05 Sterling Drug Inc. Method of use of 3-arylcarbonyl- and 3-cycloalkyl-carbonyl-1-aminoalkyl-1H-indoles
DE3533331A1 (de) 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3807381A1 (de) 1988-03-07 1989-09-21 Hoechst Ag 4,6-bis-trichlormethyl-s-triazin-2-ylgruppen enthaltende heterocyclische verbindungen, verfahren zu ihrer herstellung und lichtempfindliches gemisch, das diese verbindung enthaelt
TW205041B (es) 1989-08-07 1993-05-01 Fujisawa Pharmaceutical Co
DE4021439A1 (de) 1989-12-14 1991-06-20 Bayer Ag 2-iminopyridin-derivate
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
US5013837A (en) 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US4973587A (en) 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
EP0639569A4 (en) 1991-03-11 1995-09-20 Nippon Soda Co NEW HETEROCYCLIC COMPOUND.
CA2131191A1 (en) 1992-03-03 1993-09-04 Mitsuru Shibata Pyrazole derivatives
DE69319956T2 (de) 1992-04-30 1999-01-14 Hodogaya Chemical Co., Ltd., Tokio/Tokyo Benzothiazolederivate und diese enthaltende fungizide Zusammensetzungen für Landwirtschaft und Gartenbau
US5654322A (en) * 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
JPH07507574A (ja) 1993-04-05 1995-08-24 藤沢薬品工業株式会社 テストステロン５α−レダクターゼ阻害剤用インドール誘導体
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JPH06345736A (ja) 1993-06-14 1994-12-20 Tokuyama Soda Co Ltd ウレタン化合物を製造する方法
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
JPH10503171A (ja) 1994-05-17 1998-03-24 ダウエランコ Ｎ−（５−イソチアゾリル）アミド有害生物防除剤
ES2340142T3 (es) 1994-07-08 2010-05-31 Ev3 Inc. Sistema para llevar a cabo un procedimiento intravascular.
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
ATE257829T1 (de) 1995-09-15 2004-01-15 Upjohn Co Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6323214B1 (en) 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
US7112553B1 (en) 1999-04-20 2006-09-26 Syngenta Limited Pesticidal indazole or benzotriazole derivatives
DE19928033A1 (de) 1999-06-18 2000-12-21 Basf Ag Verwendung von cyclischen Enaminen als Lichtschutzmittel
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB9918037D0 (en) * 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
ES2222919T3 (es) 1999-08-27 2005-02-16 Abbott Laboratories Compuestos sulfonilfenilpirazoles utiles como inhibidores de cox-2.
KR100509401B1 (ko) 1999-09-14 2005-08-22 시오노기세이야쿠가부시키가이샤 2-이미노-1,3-티아진 유도체
MXPA02005101A (es) 1999-10-18 2003-09-25 Alexipharma Inc Derivados de indol canabimimeticos.
GB0002034D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
GB0006289D0 (en) 2000-03-15 2000-05-03 Smithkline Beecham Plc New use
GB0010437D0 (en) 2000-04-28 2000-06-14 Darwin Discovery Ltd Process
ES2336425T3 (es) 2000-06-30 2010-04-13 Dainippon Sumitomo Pharma Co., Ltd. Derivados de tiazoles utiles como agentes antiinflamatorios.
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
FR2816938B1 (fr) 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
ATE478670T1 (de) 2001-01-29 2010-09-15 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
WO2002102232A2 (en) 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US7949668B2 (en) 2001-08-20 2011-05-24 Pardalis, Inc. Common point authoring system for the complex sharing of hierarchically authored data objects in a distribution chain
JPWO2003029199A1 (ja) 2001-09-28 2005-01-13 武田薬品工業株式会社 ベンゼン誘導体、その製造法および用途
EP1442019B8 (en) 2001-11-01 2013-10-30 Janssen Pharmaceutica NV Amide derivatives as glycogen synthase kinase 3-beta inhibitors
US6727247B2 (en) 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
WO2003097605A1 (en) 2002-05-16 2003-11-27 Bayer Cropscience Gmbh Pesticidal pyridinecarboxamide derivatives
JP3902523B2 (ja) 2002-08-05 2007-04-11 富士フイルム株式会社 光情報記録媒体および情報記録方法
US20040077617A1 (en) 2002-10-22 2004-04-22 Bennani Youssef L. Fused cycloalkyl amides and acids and their therapeutic applications
FR2847899B1 (fr) 2002-11-29 2006-04-28 Sanofi Synthelabo Derives d'indole-3-carboxamide, leur preparation et leur application en therapeutique
US7390670B2 (en) 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
WO2005000825A1 (ja) 2003-06-27 2005-01-06 Dainippon Sumitomo Pharma Co., Ltd. チアゾールイミン類およびオキサゾールイミン類
US6964237B2 (en) 2003-06-30 2005-11-15 Mark P. Hepp Grate block for a refuse incineration grate
EP1670804A2 (en) 2003-09-10 2006-06-21 GPC Biotech AG Heterobicyclic compounds as pharmaceutically active agents
AU2004299198A1 (en) 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivates
GB0402357D0 (en) 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US20080312435A1 (en) 2004-11-15 2008-12-18 Taisho Pharmaceutical Co., Ltd. Imine Compound
CA2592378A1 (en) 2004-12-21 2006-06-29 Abbott Laboratories 3-cycloalkylcarbonyl indoles as cannabinoid receptor ligands
FR2880023B1 (fr) 2004-12-23 2007-02-23 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine leur preparation et leur application en therapeutique
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
TW200700387A (en) 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
EP1951678A1 (en) * 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity
TW200804338A (en) 2005-11-24 2008-01-16 Astrazeneca Ab New compounds
KR100778673B1 (ko) 2005-12-26 2007-11-22 주식회사 포스코 용철 제조 장치
US8841334B2 (en) 2006-05-31 2014-09-23 Abbvie Inc. Compounds as cannabinoid receptor ligands and uses thereof
RU2008152788A (ru) * 2006-05-31 2010-07-10 Эбботт Лэборетриз (Us) Новые соединения в качестве лигандов каннабиноидных рецепторов и их применение
WO2007140439A2 (en) 2006-05-31 2007-12-06 Abbott Laboratories Compounds as cannabinoid receptor ligands and uses thereof
JP2009544580A (ja) * 2006-06-27 2009-12-17 アボット・ラボラトリーズ チアゾリンおよびオキサゾリン誘導体ならびにそれらの使用方法
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
US7985768B2 (en) 2006-08-31 2011-07-26 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008028093A1 (en) 2006-08-31 2008-03-06 Abbott Laboratories Compounds as cb2 cannabinoid receptor ligands
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US7793912B2 (en) * 2006-11-08 2010-09-14 Denso Corporation Fluid pressure actuated poppet valve
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
TW200831092A (en) 2006-12-21 2008-08-01 Astrazeneca Ab Therapeutic agents
WO2008079687A1 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Novel compounds as cannabinoid receptor ligands and uses thereof
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
MX2009010363A (es) 2007-03-28 2009-12-04 Abbott Lab Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide.
US8501794B2 (en) 2007-04-17 2013-08-06 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7872033B2 (en) 2007-04-17 2011-01-18 Abbott Laboratories Compounds as cannabinoid receptor ligands
KR20100105802A (ko) * 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
CA2683086A1 (en) 2007-05-18 2008-11-18 Abbott Laboratories Color tunable light source
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
WO2009045476A1 (en) * 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
US8044071B2 (en) 2007-10-18 2011-10-25 Abbott Laboratories Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
US20090105338A1 (en) * 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
EP2222165B1 (en) 2007-11-21 2013-07-31 AbbVie Inc. Novel compounds as cannabinoid receptor ligands and uses thereof
WO2009114566A1 (en) 2008-03-11 2009-09-17 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
CN102123993A (zh) * 2008-08-15 2011-07-13 雅培制药有限公司 作为大麻素受体配体的亚胺衍生物
US8846730B2 (en) * 2008-09-08 2014-09-30 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010033543A2 (en) 2008-09-16 2010-03-25 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
CA2741047A1 (en) 2008-11-04 2010-05-14 Abbott Laboratories Novel compounds as cannabinoid receptor ligands
PA8854001A1 (es) * 2008-12-16 2010-07-27 Abbott Lab Compuestos novedosos como ligandos de receptores de canabinoides
EP2411371B1 (en) 2009-03-27 2015-05-20 AbbVie Inc. Compounds as cannabinoid receptor ligands
CN102448957A (zh) 2009-03-27 2012-05-09 雅培制药有限公司 作为大麻素受体配体的化合物
EP2411370B1 (en) 2009-03-27 2015-04-22 AbbVie Inc. Compounds as cannabinoid receptor ligands
US8586596B2 (en) 2010-06-15 2013-11-19 Abbvie Inc. Compounds as cannabinoid receptor ligands

Also Published As

Publication number Publication date
US20100069348A1 (en) 2010-03-18
US8188135B2 (en) 2012-05-29
ECSP11010974A (es) 2011-05-31
IL211406A0 (en) 2011-05-31
ES2556752T3 (es) 2016-01-20
ZA201101590B (en) 2012-08-29
CO6361998A2 (es) 2012-01-20
CN102216277A (zh) 2011-10-12
EP2428507A2 (en) 2012-03-14
AU2009293319A1 (en) 2010-03-25
CA2737199A1 (en) 2010-03-25
EP2896615A1 (en) 2015-07-22
KR20110061619A (ko) 2011-06-09
PE20110804A1 (es) 2011-11-30
WO2010033543A3 (en) 2010-11-18
AR073599A1 (es) 2010-11-17
JP2012502917A (ja) 2012-02-02
EP2428507B1 (en) 2015-10-21
BRPI0919135A2 (pt) 2015-12-08
TW201016692A (en) 2010-05-01
EP2428507A3 (en) 2012-06-13
EP2334646A2 (en) 2011-06-22
WO2010033543A2 (en) 2010-03-25
US8859596B2 (en) 2014-10-14
UY32125A (es) 2010-04-30
DOP2011000081A (es) 2011-07-15
MX2011002811A (es) 2011-04-12
RU2011115087A (ru) 2012-10-27
US20100069349A1 (en) 2010-03-18
CL2011000544A1 (es) 2011-06-17
PA8842501A1 (es) 2010-04-21

Similar Documents

Publication Publication Date Title
AR077664A2 (es) Compuestos como ligandos de receptores de canabinoides
AR074691A1 (es) Derivados de tiazol como ligandos de receptores de cannabinoides
JP2009511490A5 (es)
AR063392A1 (es) Dihidropirazolonas sustituidas con heterociclos, procedimiento de preparacion, medicamentos que las contienen y usos en el tratamiento y/o profilaxis de enfermedades cardiovasculares,hematologicas y renales.
AR096450A1 (es) Compuestos para la modulación de quinasas, y sus indicaciones
AR075955A1 (es) Utilizacion de derivados de quinazolinodiona como medicamentos para tratar y/o prevenir trastornos asociados al sistema nervioso central y/o periferico.
JP2015143283A5 (es)
AR058379A1 (es) Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas.
AR086636A1 (es) Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR074648A1 (es) Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas
AR056968A1 (es) Compuestos espiro-oxindol y composiciones farmacéuticas
AR101986A1 (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
AR098912A1 (es) Inhibidores de syk
AR087984A1 (es) Derivados biciclicos de dihidroquinolina-2-ona
AR074130A1 (es) Inhibidores de la diacilglicerol aciltransferasa
AR084913A1 (es) Derivados de aril-benzocicloalquil-amida
WO2009010660A3 (fr) Indazoles substitues, leur preparation et leur utilisation en therapeutique
AR103265A1 (es) Compuestos de azolina sustituidos con un sistema de anillos condensado
AR068888A1 (es) Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
AR073498A1 (es) Derivados de tieno [2-3-d] pirimidin
AR087793A1 (es) Compuestos de benzofurano sustituido y metodos para el uso de los mismos en el tratamiento de enfermedades virales
AR070655A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
CO6410301A2 (es) 1 aril -3- aminoalcoxi-pirazoles como ligandos sigma para potenciar ell efecto analgesico de los opioides y atenuar la dependencia de ellos
ES2603931T3 (es) Compuestos de triazolo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal